1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Dignitana AB (publ)

Dignitana AB (publ)

DIZTF
Dignitana AB (publ)US flagOther OTC
0.22
USD
- -
- -
17.99MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.54
0.55
1.13
0.18
0.29
1.13
0.83
0.74
0.77
0.88
1.11
1.22
1.16
1.13
Basic EPS, GAAP
-0.8
-0.9
-0.61
-0.64
-1.05
-2.1
-0.64
-0.69
-0.87
-0.66
-0.34
-0.25
-0.25
-0.2
Free Cash Flow per Basic Share
-0.83
-1.09
-0.55
-0.96
-1.09
-1.67
-0.78
-0.89
-0.69
-0.84
-0.32
-0.15
-0.05
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.18
-3.48
-4.15
0.14
-0.39
-0.1
0.56
0.65
0.11
0.1
0.11
0.1
-3.3
0.1
Tangible Book Value per Share
1.49
1.61
0.26
1.04
1.36
1.96
0.89
0.59
1.01
0.31
0.26
0.07
0.09
0.05
Basic Weighted Avg Shares
17
18
18
26
31
20
41
55
61
65
66
70
78
80
Sales/Revenue/Turnover
9
10
20
5
9
23
34
41
47
57
73
86
90
91
Operating Margin (%)
-144.16
-167.05
-55.47
-356.12
-389.38
-177.63
-71.5
-92.95
-115.46
-82.69
-41.16
-17.46
-20.37
-16.51
Depreciation Expense
- -
- -
- -
1
4
7
8
10
24
13
14
15
13
12
Net Income, GAAP
-13
-16
-11
-17
-32
-43
-26
-38
-53
-43
-22
-17
-19
-16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-147.51
-162.94
-53.67
-348.89
-362.49
-185.69
-77.12
-93.45
-113.58
-75.49
-30.7
-20.17
-21.35
-17.63
Working Capital
24
21
3
25
32
27
24
12
36
6
-1
-9
-5
-5
LT Debt
- -
- -
- -
- -
- -
6
3
2
2
16
9
6
- -
- -
Total Equity
27
32
15
41
56
51
55
55
78
31
24
7
7
4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
-130.12
-249.88
-662.25
-330.72
-246.39
- -
-211.72

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
8
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
81
Market Capitalization
100
112
138

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
22
20
17
Cash, Cash Equivalents & STI
4
3
3
Accounts Receivable, Net
4
6
4
Inventories
10
8
7
Total Current Liabilities
24
25
22
Payables & Accruals
- -
- -
- -
ST Debt
8
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.27%
-22.66%
-2.06%
Free Cash Flow
8.01%
-31.41%
-60.56%
Net Income, GAAP
14.64%
-7.89%
10.46%
Sales/Revenue/Turnover
32.34%
17.43%
4.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
21
21
22
21
86
2024
21
22
23
24
90
2025
22
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.06
-0.07
-0.05
-0.07
-0.25
2024
-0.07
-0.14
-0.02
-0.01
-0.25
2025
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Fredrik Jonsson
Full Time Employees
26
Sector
Healthcare
Industry
Medical - Devices
Address
Traktorgränden 3 Lund Sweden 226 60
IPO Date
May 18, 2015
Website
dignitana.com
Similar Companies
Coloplast A/S (CLPBF)
Medicalgorithmics S.A. (MDG.WA)
Abbott Laboratories (ABT)
OrthoPediatrics Corp. (KIDS)
Zhejiang Tailin BioEngineering Co.,Ltd (300813.SZ)
Getinge AB (publ) (GETI-B.ST)
Business
Dignitana AB (publ) develops, produces and markets the DigniCap Scalp Cooling System, a patented medical cooling device that minimizes hair loss during chemotherapy for cancer patients with solid tumors including breast, ovarian, prostate, uterine and lung cancers; the system, FDA-cleared since 2015 with expanded clearance in 2017, provides continuous cooling via silicone caps and the compact DigniCap Delta unit for improved clinic usability and patient comfort, available in over 260 US infusion centers and 30 countries worldwide. Founded in 2007 and headquartered in Lund, Sweden, the company maintains operations in Dallas, Texas through wholly-owned subsidiary Dignitana, Inc. and a subsidiary Dignitana S.r.l. in Milan, Italy, targeting oncology clinics, hospitals and healthcare providers in the medical devices sector focused on chemotherapy side-effect management. In 2025, Paxman AB (publ) completes a recommended takeover offer acquiring approximately 86.6% of Dignitana shares (with commitments reaching 92.2%), issues new shares as consideration valuing Dignitana at SEK 153 million, extends the acceptance period through May, plans compulsory redemption of remaining shares and delisting from Nasdaq First North Growth Market by June 2025 following Dignitana's annual general meeting, merging the scalp cooling leaders to achieve synergies in revenue, costs, market expansion and R&D.